You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Myeloma

Showing 51 - 75 of 4,176
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023

Real-world Usage of HyQvia in Multiple Myeloma Secondary

Not yet recruiting
  • Multiple Myeloma
  • Secondary Immunodeficiency (SID)
  • No Intervention
  • (no location specified)
May 19, 2023

Myeloma Multiple, Myeloma, Refractory Multiple Myeloma Trial in Brooklyn, New York (Selinexor, Clarithromycin, Pomalidomide)

Terminated
  • Myeloma Multiple
  • +2 more
  • Brooklyn, New York
  • +1 more
Jan 24, 2023

Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)

Recruiting
  • Multiple Myeloma
  • APRIL-BAFF-Bicephali CAR-T cells
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 14, 2023

Health Technology Intervention on Patient Activation in Multiple

Not yet recruiting
  • Multiple Myeloma in Relapse
  • +3 more
    • (no location specified)
    Jan 9, 2023

    Multiple Myeloma Trial in Paris (Idecabtagene vicleucel, Not treated)

    Active, not recruiting
    • Multiple Myeloma
    • Idecabtagene vicleucel
    • Not treated
    • Paris, France
      DESCAR-T Registry
    Nov 27, 2023

    Multiple Myeloma Trial in São Paulo (Single-dose involved-site radiotherapy)

    Recruiting
    • Multiple Myeloma
    • Single-dose involved-site radiotherapy
    • São Paulo, Sao Paulo, Brazil
      University of Sao Paulo
    Aug 9, 2023

    Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • YTS104 Cells injection
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jun 13, 2023

    Multiple Myeloma, Myeloma Multiple, Myeloma Trial in Poitiers (Drug and medical device)

    Not yet recruiting
    • Multiple Myeloma
    • +2 more
    • Drug and medical device
    • Poitiers, France
      CHU Poitiers
    Jun 1, 2023

    Lymphoma, Multiple Myeloma Trial in Chongqing (pegylated recombinant human granulocyte-colony stimulating factor)

    Recruiting
    • Lymphoma
    • Multiple Myeloma
    • pegylated recombinant human granulocyte-colony stimulating factor
    • Chongqing, Chongqing, China
      Chongqing University Cancer Hospital
    Sep 23, 2023

    Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

    Recruiting
    • Multiple Myeloma
    • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Aug 11, 2023

    Multiple Myeloma Trial in Los Angeles (Penguin Cold Cap)

    Recruiting
    • Multiple Myeloma
    • Penguin Cold Cap
    • Los Angeles, California
      Cedars-Sinai Medical Center
    Jul 27, 2023

    Multiple Myeloma Cells From miRNAs Released From B Cells, and

    Recruiting
    • Multiple Myeloma
      • Aviano, Pordenone, Italy
        Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
      Nov 23, 2023

      Smoldering Multiple Myeloma Trial (Selinexor)

      Not yet recruiting
      • Smoldering Multiple Myeloma
      • (no location specified)
      Oct 27, 2022

      Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,

      Not yet recruiting
      • Multiple Myeloma
      • Renal Failure
      • Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
      • Augusta, Georgia
        Georgia Cancer Center-Augusta University
      Nov 16, 2023

      Multiple Myeloma Trial in Suzhou (Tocilizumab)

      Recruiting
      • Multiple Myeloma
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      May 3, 2023

      Multiple Myeloma Trial in Rochester (behavioral, other, procedure)

      Not yet recruiting
      • Multiple Myeloma
      • Supportive Care (home-based physical activity)
      • +5 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Nov 22, 2023

      Stem Cells Mobilization, colLection and Engraftment in Newly

      Recruiting
      • Multiple Myeloma
      • +3 more
      • Rome, Italy
        Fondazione Policlinico Universitario A.Gemelli IRCCS
      Apr 28, 2023

      Multiple Myeloma Trial in Roma, Rome (ChIP-seq, NGS, ATAC-seq)

      Recruiting
      • Multiple Myeloma
      • ChIP-seq, NGS, ATAC-seq
      • Roma, Italy
      • +1 more
      May 24, 2023

      Multiple Myeloma, Plasma Cell Myeloma Trial in San Francisco (drug, procedure, other)

      Not yet recruiting
      • Multiple Myeloma
      • Plasma Cell Myeloma
      • Zirconium Zr 89-DFO-YS5
      • +3 more
      • San Francisco, California
        University of California, San Francisco
      May 26, 2023

      Multiple Myeloma Trial in Augusta (Lenalidomide, Vitamin D - Intensified, Vitamin D - Therapeutic)

      Not yet recruiting
      • Multiple Myeloma
      • Augusta, Georgia
        Georgia Cancer Center at Augusta University
      Apr 26, 2023

      Multiple Myeloma Trial in Birmingham (ARM A EARLY INTERVENTION GROUP, ARM B DELAYED INTERVENTION GROUP)

      Active, not recruiting
      • Multiple Myeloma
      • ARM A EARLY INTERVENTION GROUP
      • ARM B DELAYED INTERVENTION GROUP
      • Birmingham, Alabama
        University of Alabama at Birmingham
      Nov 29, 2022

      Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

      Not yet recruiting
      • Multiple Myeloma, Refractory
      • Multiple Myeloma in Relapse
      • Autologous CAR-T cell therapy expressing the BAFF-ligand.
      • Cleveland, Ohio
        University Hospitals Seidman Cancer Center
      Jan 11, 2023

      Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

      Not yet recruiting
      • Relapsed/ Refractory Multiple Myeloma
      • GC012F
      • (no location specified)
      Apr 28, 2023

      Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)

      Recruiting
      • Relapsed or Refractory Multiple Myeloma
      • Tianjin, Tianjin, China
        Institute of Hematology & Blood Diseases Hospital
      Jun 24, 2023